Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Operating margin-345.2%-43.8%
Net margin-302.6%-31.2%
Returns
Return on equity-32.6%-16.9%
Return on invested capital-46.4%-59%
Efficiency
Asset turnover0.1×-0.4×0.3×+0.1×0.5×+0.4×0.5×+0.5×0.5×+0.5×
Liquidity
Current ratio9.5×+3.9×6.1×+3.7×6.5×+0.5×7.2×+0.6×5.6×+0.8×
Leverage
Debt-to-equity0.1×-0.1×0.2×0.0×0.2×0.0×0.2×0.0×0.2×-0.1×
Per Share
Book value per share$5.23+57.5%$2.81-7.0%$2.98+19.1%$3.26+3.4%$3.32+30.8%
Valuation
Market capitalization$1.32B+361%$1.02B+139%$457.64M+5.3%$291.56M+9.4%$285.41M-32.7%
Price / sales30.6×+28.9×8.3×+2.6×2.5×-26.5×1.6×-44.6×1.8×-397×
Price / book2.5×+1.5×4.4×+2.5×1.9×-0.3×1.1×-0.1×-1.7×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Monte Rosa Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Monte Rosa Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.